Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 2XP HEPTAVAX™-II SC, RECOMBIVAX HB, 1XP HEPTAVAX™-II SC
HBVAXPRO · 1 trial · 1 indication
Participant serum samples were collected for analysis with an enhanced chemiluminescence (ECi) assay to determine the concentration of antibodies to hepatitis B surface antigen (HBsAg). Response rate was the percentage of participants with a protective hepatitis B surface antibody (anti-HBs) level of ≥ 10 mIU/mL at Day 30 post-challenge.
| Arm | Type | Description |
|---|---|---|
| HBVAXPRO™ | EXPERIMENTAL | Healthy children vaccinated approximately 8-9 years previously with a 2- or 3-dose infant series and toddler dose of Vaxelis® who will receive a single dose of Hepatitis B vaccine challenge (HBVAXPRO™). |
| Name | Type | Description |
|---|---|---|
| HBVAXPRO™ | BIOLOGICAL | Single 0.5 mL intramuscular dose |
Inclusion Criteria: * Is healthy (based on a review of medical history and targeted physical examination) based on the clinical judgment of the investigator. * Has participated in Protocol V419-007 and received a 3 + 1 Vaxelis® schedule or participated in Protocol V419-008 and received a 2 + 1 Vaxe...
Top 6 of 8 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Gilead Sciences, Inc. | GILD | 3 | PHASE3 | Viread, Tenofovir alafenamide |
| Vir Biotechnology, Inc. | VIR | 6 | PHASE3 | Tobevibart, Elebsiran |
| Bausch Health Companies Inc. | BHC | 1 | PHASE3 | Larsucosterol |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Daplusiran/Tomligisiran, Bepirovirsen |
| Aligos Therapeutics, Inc. | ALGS | 1 | PHASE2 | ALG-000184 |
| Precision BioSciences, Inc. | DTIL | 2 | PHASE1 | PBGENE-HBV |
HBVAXPRO is used for protection against hepatitis B, an infectious disease of the liver. It is a vaccine candidate developed by Merck & Company, Inc. (ticker MRK) and is given to prevent hepatitis B infection. The program has been studied in a Phase 3 hepatitis B vaccine challenge trial.
HBVAXPRO is made by Merck & Company, Inc., which trades under the ticker MRK. Merck is the developer of the hepatitis B vaccine candidate. The company has sponsored the clinical trial evaluating HBVAXPRO in hepatitis B.
HBVAXPRO is in Phase 3 development for hepatitis B. The program has one completed Phase 3 trial and no active trials. It is an investigational vaccine candidate and is not described as approved.
HBVAXPRO has been studied in one completed Phase 3 trial, NCT04490499, titled A Hepatitis B Vaccine Challenge Study After Previous Vaxelis Vaccination (V419-013). The trial enrolled 207 participants in Finland, included both sexes, and had a minimum age of 8 years. It was an uncontrolled study.
Yes, HBVAXPRO and HBVAXPRO™ refer to the same hepatitis B vaccine candidate from Merck & Company, Inc. The trademark symbol is simply a stylized version of the same name. Both names point to the same Phase 3 program for hepatitis B.